Clinical Research Directory
Browse clinical research sites, groups, and studies.
2 clinical studies listed.
Filters:
Tundra lists 2 BRAF V600E Mutation clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT06610682
Feasibility of CSF and Plasma ctDNA in BRAF-altered Glioma During Treatment With Plixorafenib
Evaluating the sensitivity and feasibility of using ctDNA assays optimized for detecting very low ctDNA counts from cerebrospinal fluid (CSF) and plasma. The investigators will evaluate the sensitivity of ctDNA from plasma and CSF at baseline (defined as Cycle1 Day1 (C1D1) pre-treatment) and over time in response to treatment with plixorafenib co-administered with cobicistat in BRAF-V600E mutant glioma refractory to prior therapies.
Gender: All
Ages: 18 Years - Any
Updated: 2025-12-10
1 state
NCT05988697
Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib
The purpose of this study is to observe the safety and efficacy of Aspirin combined with Trametinib and Dalafenib in the treatment of advanced BRAF V600E mutated non-small cell lung cancer (NSCLC)
Gender: All
Ages: 18 Years - 75 Years
Updated: 2023-10-12